Overview

A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate

Status:
NOT_YET_RECRUITING

Trial end date:
2029-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to find out whether talazoparib in combination with enzalutamide or talazoparib alone delays cancer progression in people with metastatic castration-resistant prostate cancer (mCRPC) who have homologous recombination repair (HRR) mutations and have previously received abiraterone acetate.

Phase:

PHASE2

Details

Lead Sponsor:

Prostate Cancer Clinical Trials Consortium

Collaborators:

Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
Pfizer

Treatments:

enzalutamide
talazoparib